Simponi Maintains Long-Term Effects in UC Patients, GO-COLITIS Results Show

Simponi Maintains Long-Term Effects in UC Patients, GO-COLITIS Results Show
Results from the GO-COLITIS clinical trial (NCT02092285) confirm that the long-term effects of Janssen Pharmaceutical’s Simponi (golimumab) were maintained in patients with ulcerative colitis (UC), according to MSD, sponsor of the study. The United Kingdom (UK)-based study confirmed the effectiveness of the drug in inducing and maintaining clinical response during the 66 weeks of treatment since the beginning of the trial. “We are encouraged by the proportion of patients who maintained clinical response up to and beyond one year, and what this means to patients in terms of disease control,” Chris Probert, MD, lead study investigator, said  in a press release. Probert is a professor at the University of Liverpool, UK. The results were presented by MSD — known as Merck in the U.S. and Canada — at the 25th United European Gastroenterology week, Oct. 27-Nov. 1 in Barcelona, Spain.  GO-COLITIS is designed to evaluate the effectiveness of Simponi in the treatment of ulcerative colitis. Researchers analyzed the induction and maintenance of clinical response in 205 patients. Patients included had moderate-to-severe UC and were not treated with any human tumor necrosis factor (TNF)-alpha type prior to initiation of the clinical trial.  The Phase 4 results presented were a follow-up of the study after assessment at six weeks. After the six weeks, 141 of the 205 patients (68.8%) reacted to once-monthly treatment with Simponi. These 141 patients were followed for the next 60 weeks, designated as the maintenance phase. At 54 weeks, 52 of the 140 patients (37.1%) had maintained clinical response, and almost one third of the 140 patients (42, 30%) were in clinical remission. In addition, patients reported improvements in quality of life through th
Subscribe or to access all post and page content.